Facing several class action lawsuits and questions concerning revenue from its Korean business, Belgian speech-recognition firm Lernout & Hauspie announced that long-time president and CEO Gaston Bastiaens has stepped down. John Duerden, formerly
Facing several class action lawsuits and questions concerning revenue from its Korean business, Belgian speech-recognition firm Lernout & Hauspie announced that long-time president and CEO Gaston Bastiaens has stepped down.
John Duerden, formerly president and CEO of Dictaphone and L&Hs Healthcare Solutions Group (HSG), will take on leadership of the speech technologies firm. Robert Schwager, who served under Duerden as general manager of Dictaphones healthcare business and L&H HSG, will become president of L&H HSG. Bastiaens remains a board member.
Bastiaens had come under fire in recent months for focusing on growing L&Hs business through acquisitions rather than concentrating on its core speech recognition products. In fact, the company has been broadening its technology base in the face of stiff competition in the speech and voice technologies field, where the major players include IBM, Nuance Communications, SpeechWorks, and Philips Electronics.
Duerden plans to focus on better integrating Dictaphone and Dragon Systems into L&Hs operations. Dictaphone and Dragon Systems are among half a dozen companies acquired by L&H in the past year. Industry sources estimate that L&H achieved a 60% share of the $6 billion medical transcription market through the Dictaphone acquisition. Dictaphones healthcare division accounted for $11.2 million of the companys $155 million in revenue for second-quarter 2000.
L&H sales have fallen off everywhere except Korea. U.S. revenue totaled $48.2 million for second-quarter 2000, up from $18.7 million in second-quarter 1999, but the increase was attributed to revenue from Dictaphone and Dragon Systems. L&H stock has lost more than half its value since reaching a 52-week high of $72.50 in early spring. The stock closed at $29.75 per share Aug. 30. In addition, the firm filed a shelf registration statement with the Securities and Exchange Commission in early August to sell up to $250 million in stock to pay off bank debt and provide working capital.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.